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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
This review will evaluate the benefits and harms of dietary patterns among adults with CKD (any stage including people with end-
stage kidney disease (ESKD) treated with dialysis, transplantation or supportive care).
B A C K G R O U N D
Description of the condition
Chronic kidney disease (CKD) is a disorder resulting from struc-
tural changes to the kidney (cysts, loss of tissue, or masses) and/or
urinary tract leading to changes in the composition of the urine
and/or reduced kidney function. The kidney is a target organ in-
jured in diseases primary to the kidney (such as glomerulonephritis
or polycystic kidney disease) and secondary diseases (including car-
diovascular disease, metabolic syndrome, diabetes (predominantly
type 2), obesity, and arterial hypertension). Secondary causes of
kidney failure now dominate the global epidemiology of kidney
disease - diabetes and hypertension are the leading causes of CKD
in middle and higher income countries worldwide, accounting for
approximately 35% and 25% of kidney disease (Jha 2013). Kid-
ney tissue in systemic diseases is injured by accelerated vascular
damage, glomerular hypertension, and increased cellular glycosy-
lation and oxidation.
Overall, CKD affects an estimated 10% to 15% of people around
the world (Chadban 2003; Singh 2009; Zhang 2012) and leads to
poorer health outcomes for affected individuals and communities.
Among people who havemoderate to severe CKD, early death and
cardiovascular complications are two to three times more likely
than for peoplewithout kidney disease andquality of life is reduced
(Go 2004; Hemmelgarn 2010; Wyld 2012).
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Description of the intervention
Dietary patterns (dietary intake of whole foods rather than single
dietary nutrients, such as sodium or protein) may play an impor-
tant and complex role in the aetiology and progression of CKD,
in part through modification of systemic disease processes affect-
ing kidney function (arterial hypertension, tissue glycosylation,
glomerular injury, and macrovascular and microvascular diseases)
and in part through altering the risks of non-communicable dis-
eases such as diabetes that play such an important role in the
prevalence of kidney disease in developed and developing nations.
Individual dietary components may influence blood lipid levels,
oxidative stress, insulin sensitivity, blood pressure, systemic in-
flammatory responses, pro fibrotic processes, thrombosis risk, and
endothelial function to modify clinical outcomes (Abiemo 2012;
Nakayama 1996; Peters 2000; Stamler 1996; van Dijk 2012).
While the exactmechanisms throughwhich dietary patternsmight
act to prevent or slow CKD progression are likely to be multifac-
torial, there is emerging evidence showing the impact of dietary
modification on risk factors for kidney injury. In recent Cochrane
reviews of dietary advice in broader populations - predominantly
by reduction of salt and fat intake and increases in fruit, vegeta-
bles, and fibre intake - dietary changes reduced arterial blood pres-
sure by 2.61 mm Hg on average, as well as serum cholesterol and
sodium excretion (Hartley 2013; Rees 2013a; Rees 2013b). Com-
bined dietary and exercise interventions among people at risk of
diabetes reduce weight and body mass and have modest effects
on blood lipids and blood pressure, while altered carbohydrate or
energy intake plus exercise improves glycaemic control in people
with type 2 diabetes (Nield 2008; Orozco 2008). Intensive advice
and support to reduce salt intake may have small and unsustained
effects on blood pressure (Adler 2014) of uncertain clinical im-
portance.
Although numerous randomised controlled trials (RCTs) in peo-
ple with CKD have evaluated single nutrient management (such
as protein intake), there is relatively less information about the im-
pact of dietary patterns that consider whole foodmodification - for
example, Mediterranean Diet or Dietary Approaches to Stop Hy-
pertension (DASH) - on clinical outcomes in people with CKD.
Clinical studies in this area have been largely restricted to mod-
ifying protein, sodium, and phosphorus dietary intake as well as
antioxidant supplementation (Fouque 2009; Jun 2012; Liu 2015;
McMahon 2015). Among people with CKD, lowered dietary salt
intake reduced blood pressure and the amount of protein excreted
by the kidney (an indicator of cardiovascular risk) (McMahon
2015), although there was no high-quality evidence this translated
to slower kidney disease progression or fewer cardiovascular com-
plications. Although dietary interventions in the setting of CKD
have commonly focused on protein restriction as a mechanism to
slow kidney failure, there is limited evidence that this dietary strat-
egy is effective and safe and the impact of different protein sources
on clinical outcomes is poorly understood (Robertson 2007).
Why it is important to do this review
Global clinical guidelines recommend dietary strategies in the
management of CKD (KDIGO 2012). Specifically, guidelines in-
clude suggestions to lower protein intake with appropriate edu-
cation and avoid high protein intake for people at risk of kidney
disease progression, lower salt intake and increase physical activity
(aiming for at least 30 minutes, 5 times/week). Guidelines rec-
ommend that people with CKD receive dietary advice and infor-
mation in the context of an education program that is tailored
to the severity of their CKD and the need to modify salt, phos-
phate, potassium, and protein intake. Given these guidelines, up
to date evidence of the benefits and harms of dietary management
is needed to inform practice and policy.
In addition, patients, caregivers and health professionals consider
the effects of dietarymanagement as important and a priority treat-
ment uncertainty in CKD (Manns 2014). When speaking about
dietary strategies, some patients experience dietary restrictions as
an intense and unremitting burden (Palmer 2015), while at the
same time offering them greater self-efficacy in themanagement of
their CKD. In general, patients value better understanding of the
role of lifestyle management as a research priority (Tong 2015).
Dietary management is therefore an important potential interven-
tion for improving clinical outcomes in CKD that aligns with pa-
tient priorities.
O B J E C T I V E S
This review will evaluate the benefits and harms of dietary patterns
among adults with CKD (any stage including people with end-
stage kidney disease (ESKD) treated with dialysis, transplantation
or supportive care).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include RCTs and quasi-RCTs (in which allocation to
treatment was obtained by alternation, use of alternate medical
records, date of birth, or other predictable methods) measuring
the effect of dietary patterns in adults with CKD.
Types of participants
Inclusion criteria
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Adults with any stage of CKD (any structural kidney or urine ab-
normality with or without reduced glomerular filtration rate below
60 mL/min/1.73 m² as defined by the Kidney Disease: Improving
Global Outcomes (KDIGO 2012)) including people with ESKD
treated with dialysis, kidney transplantation or supportive care.
Exclusion criteria
Pregnant women and children younger than 18 years.
Types of interventions
Inclusion criteria
We will evaluate the following dietary patterns (including dietary
advice or lifestyle management) compared with any other dietary
pattern or standard care (including lifestyle advice).
• Dietary patterns (e.g. DASH diet; Mediterranean diet,
American Heart Association diet)
• Nutritional counselling and education about food-based
dietary interventions
• Lifestyle advice about dietary intake
We will include studies evaluating treatment for at least one
month and studies in which concomitant non-randomised inter-
ventions such as antihypertensive medication, sodium restriction,
or other co-interventions including supplements were used during
the study period (e.g. specific blood pressure targets), providing
that these interventions were administered to all treatment groups.
These means we will include studies of dietary patterns regardless
of whether other dietary modifications such as salt or phosphorus
dietary intake were adjusted. We will not include differing levels
of energy intake as interventions in the review.
Exclusion criteria
We will exclude dietary management interventions that are “sin-
gle-nutrient” or nutrient-focused interventions (including supple-
mentation). This will include the following dietary management
interventions.
• Dietary management of specific dietary factors including
sodium, phosphorus, and protein (as these are evaluated in other
Cochrane reviews (Fouque 2009; Jun 2012; Liu 2015;
McMahon 2015)
• Probiotics
• Parenteral, intra-dialysate or intra-peritoneal dietary
supplementation
• Implementation strategies for dietary or lifestyle
management
Types of outcome measures
We will categorise outcomes according to length of follow up (<
6 months and ≥ 6 months). We will extract and analyse data for
shorter (< 6 months) and longer (≥ 6 months) term outcomes
separately.
Primary outcomes
1. All-cause mortality
2. Major adverse cardiovascular events (as defined by study
investigators)
3. Health-related quality of life (as defined and measured by
investigators)
Secondary outcomes
1. Withdrawal from dietary intervention
2. Cause-specific death (cardiovascular mortality, sudden
death, infection-related mortality)
3. Progression to ESKD (as defined by the investigators
including estimated glomerular filtration rate below 15 mL/min/
1.73 m² or requiring treatment with long-term dialysis or kidney
transplantation)
4. Participant adherence to intervention
5. Myocardial infarction
6. Kidney function measures (creatinine clearance or
estimated glomerular filtration rate, doubling of serum
creatinine, serum creatinine)
7. Serum lipids (total cholesterol, low density lipoprotein
(LDL) cholesterol, triglycerides)
8. Blood pressure
9. Blood glucose control (glycated haemoglobin; fasting
plasma glucose)
10. Global measures of nutritional status (body mass index;
body weight; waist circumference; subjective global assessment;
malnutrition screening tool; mini nutritional assessment; skin-
fold measurements; bioelectrical impedance analysis; albumin;
prealbumin)
Search methods for identification of studies
Electronic searches
We will search the Cochrane Kidney and Transplant Specialised
Register through contact with the Trials Search Co-ordinator us-
ing search terms relevant to this review. The Specialised Register
contains studies identified from several sources.
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL)
2. Weekly searches of MEDLINE OVID SP
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3. Handsearching of kidney-related journals and the
proceedings of major kidney conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected kidney journals
6. Searches of the International Clinical Trials Register
(ICTRP) Search Portal and ClinicalTrials.gov.
Studies contained in the SpecialisedRegister are identified through
search strategies for CENTRAL,MEDLINE, andEMBASE based
on the scope of Cochrane Kidney and Transplant. Details of these
strategies, as well as a list of handsearched journals, conference
proceedings and current awareness alerts, are available in the Spe-
cialised Register section of information about Cochrane Kidney
and Transplant.
See Appendix 1 for search terms used in strategies for this review.
Data collection and analysis
Selection of studies
The search strategy will be used to obtain titles and abstracts of
studies that might have been relevant to the review. The titles and
abstracts will be screened independently by at least two authors,
who will discard studies that are not eligible; however, studies
and reviews that might include relevant data or information on
studies will be retained initially. Two authors will independently
assess retrieved abstracts and, if necessary the full text, of these
studies to determine which studies satisfied the inclusion criteria.
Any uncertainties about study eligibility will be discussed between
authors and if necessary with a third author.
Data extraction and management
Data extraction will be carried out independently by two au-
thors using pre-specified standard data extraction forms. Studies
reported in non-English language journals will be electronically
translated before assessment. Where more than one publication
of one study exists, study reports will be grouped together and
the publication with the most complete data will be used in the
analyses. Where relevant outcomes are only published in earlier
publications of the study, these data will used. Any discrepancy
between published versions will be evaluated and highlighted.
Assessment of risk of bias in included studies
The following reporting items will be independently assessed by
two authors using the risk of bias assessment tool (Higgins 2011)
(see Appendix 2):
• Was there adequate sequence generation (selection bias)?
• Was allocation adequately concealed (selection bias)?
• Was knowledge of the allocated interventions adequately
prevented during the study?
◦ Participants and personnel (performance bias)
◦ Outcome assessors (detection bias)
• Were incomplete outcome data adequately addressed
(attrition bias)?
• Are reports of the study free of suggestion of selective
outcome reporting (reporting bias)?
• Was the study apparently free of other problems that could
put it at a risk of bias
Measures of treatment effect
For dichotomous outcomes (total and cause-specific mortality,
myocardial infarction, progression to ESKD, doubling of serum
creatinine, participant adherence, withdrawal from intervention),
the treatment effects of dietary management will be expressed as
a risk ratio (RR) together with 95% confidence intervals (CI).
Where continuous scales of measurement are used to assess the
effects of dietary management (health-related quality of life, blood
pressure, lipids (total cholesterol, LDL cholesterol, triglycerides),
kidney function (serum creatinine, creatinine clearance, glomeru-
lar filtration rate), body composition (weight, waist circumference,
body mass index)), the mean difference (MD) between treatment
groups will be used, or the standardised mean difference (SMD) if
different measurement scales have been reported.We will evaluate
mean end of treatment values for continuous outcomes together
with the reported standard deviation in meta-analyses for these
continuous outcomes.
Unit of analysis issues
Studies with non-standard designs will be analysed in this review
including cross-over RCTs, studies with more than two interven-
tions, and cluster RCTs. We will use recommended methods for
data extraction and analysis described by the Cochrane Collabo-
ration (Higgins 2011).
Cross-over studies
Cross-over studies will be included in this meta-analysis. How-
ever, as carry-over of the dietary intervention given in the first pe-
riod is likely to persist into subsequent treatment periods due to
behaviour modification, we will only include data for end points
reported during the first period of study in studies in which the
order of receiving treatments was randomised.
Studies with more than two interventions
Studies with multiple intervention groups will be included. When
a study was a ’multi-arm’ study, and all treatment arms provided
data for eligible interventions, the study will be described and in-
cluded in the systematic review. If there are adequate data from the
study, then treatment arms relevant to the treatment comparisons
of interest will be included in applicable meta-analyses.
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Cluster randomised studies
We will include data from cluster RCTs in meta-analyses accord-
ing to recommendations from the “Cochrane Handbook for Sys-
tematic Reviews of Interventions”, namely that the effective sam-
ple size for each data point is divided by a quantity called the de-
sign effect calculated as 1 + (M - 1) ICC, where M is the aver-
age cluster size and ICC is the intra-cluster correlation coefficient
(Higgins 2011). A common design effect will be assumed across
intervention groups. The intra-cluster coefficient (ICC) is seldom
available in published reports. We will therefore adopt a common
approach to use external estimates obtained from similar studies.
For dichotomous outcomes, both the number of participants and
the number experiencing the event will be divided by the design
effect. For continuous data, only the sample size will be divided by
the design effect with means and standard deviations remaining
unchanged. However, as resulting data for dichotomous outcomes
must be rounded to whole numbers for entry into RevMan, this
approach will be considered unsuitable for studies with a small
sample size (e.g. fewer than 50 participants overall).
We will consider the following potential sources of bias in available
cluster RCTs.
1. Recruitment bias
2. Baseline imbalance
3. Loss of clusters; and
4. Incorrect analyses.
Dealing with missing data
Any further information required from the original author will re-
quested by electronic mail and any relevant information obtained
in this manner will be included in the review. Evaluation of im-
portant numerical data such as screened, randomised patients as
well as intention-to-treat, as-treated and per-protocol population
will be carefully performed. Attrition rates, for example drop-outs,
losses to follow-up and withdrawals will be investigated. Issues of
missing data and imputation methods (for example, last-observa-
tion-carried-forward) will be critically appraised (Higgins 2011).
Assessment of heterogeneity
Statistical heterogeneity in treatment effects among studies will be
analysed using a Chi² test on N-1 degrees of freedom, with an
alpha of 0.05 used for statistical significance and with the I² test
(Higgins 2003).We will consider I² values of 25%, 50% and 75%
as corresponding to low, medium and high levels of heterogeneity,
respectively.
Assessment of reporting biases
If possible, funnel plots will be used to assess for the potential
existence of small study bias for the outcome of all-cause mortality.
In any analysis including data from10 ormore studies andwithout
evidence of statistically important heterogeneity, we will construct
funnel plots for the log risk ratio in individual studies plotted
against the SE of the risk ratio to assess for plot asymmetry.
Data synthesis
Wewill group studies by dietary patterns into similar interventions
(e.g. low-fat; Mediterranean; high fibre; increased fruits and veg-
etables). Treatment estimates for the specified will be summarised
within groups of dietary patterns and treatment effects will be
summarised using random-effects meta-analysis. Effects will be re-
ported as the relative risk (RR) and 95% confidence interval (CI)
for binary outcomes and mean difference (MD) and 95% CI for
continuous outcomes.
We will summarise information for outcomes in which meta-anal-
ysis is not possible due to insufficient observations using narra-
tive tables. Narrative outcome reporting will particularly include
health-related quality of life domains described in the studies and
nutrition assessments. The dietary interventions and associated
implementation strategies will be described using the “Better re-
porting of interventions: template for intervention description and
replication (TIDieR) checklist and guide” (Hoffmann 2014) and
tabulated in the review.
Subgroup analysis and investigation of heterogeneity
Subgroup and univariate meta-regression analysis will be used to
explore possible sources of heterogeneity (e.g. intervention du-
ration, baseline nutritional status, baseline serum cholesterol or
phosphorus level, blood pressure, stage of CKD, study risk of
bias (allocation concealment), date of publication, sample size).
We will explore the following pre-specified study-level covariate
as potential sources of heterogeneity: mean study age, mean pro-
portion of men, stage of CKD (CKD not treated with dialysis
or transplantation, CKD treated with dialysis, CKD treated with
transplantation), energy intake, study-level mean blood pressure
or cholesterol at baseline, proportion with diabetes, adequacy of
allocation concealment, sample size, and duration of follow up (<
12 months versus ≥ 12 months).
Sensitivity analysis
Where sufficient extractable data are available, we will perform
sensitivity analyses in order to explore the influence of the follow-
ing factors on effect size.
• Repeating the analysis excluding unpublished studies
• Repeating the analysis taking account of risk of bias, as
specified above
• Repeating the analysis excluding any very long or large
studies to establish how much they dominated the results
• Repeating the analysis excluding studies using the following
filters: diagnostic criteria, language of publication, source of
funding (industry versus other), and country.
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’Summary of findings’ tables
We will present the main results of the review in ’Summary of
findings’ tables. These tables present key information concerning
the quality of the evidence, the magnitude of the effects of the
interventions examined, and the sum of the available data for the
main outcomes (Schunemann 2011a). The ’Summary of findings’
tables also include an overall grading of the evidence related to
each of the main outcomes using the GRADE (Grades of Recom-
mendation, Assessment, Development and Evaluation) approach
(GRADE 2008). The GRADE approach defines the quality of
a body of evidence as the extent to which one can be confident
that an estimate of effect or association is close to the true quan-
tity of specific interest. The quality of a body of evidence involves
consideration of within-trial risk of bias (methodological quality),
directness of evidence, heterogeneity, precision of effect estimates
and risk of publication bias (Schunemann 2011b).
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A P P E N D I C E S
Appendix 1. Electronic search strategies
Database Search terms
CENTRAL 1. MeSH descriptor: [Diet] explode all trees
2. MeSH descriptor: [Diet Therapy] explode all trees
3. MeSH descriptor: [Dietary Carbohydrates] explode all trees
4. MeSH descriptor: [Calcium, Dietary] this term only
5. MeSH descriptor: [Potassium, Dietary] this term only
6. MeSH descriptor: [Dietary Fats] explode all trees
7. MeSH descriptor: [Dietary Fiber] explode all trees
8. MeSH descriptor: [Dietary Proteins] explode all trees
9. MeSH descriptor: [Dietary Supplements] this term only
10. MeSH descriptor: [Micronutrients] explode all trees
11. MeSH descriptor: [Nutritional Requirements] explode all trees
12. MeSH descriptor: [Nutritional Status] this term only
13. MeSH descriptor: [Nutrition Therapy] this term only
14. MeSH descriptor: [Keto Acids] explode all trees
15. MeSH descriptor: [Amino Acids, Essential] explode all trees
16. MeSH descriptor: [Folic Acid] this term only
17. MeSH descriptor: [Patient Education as Topic] this term only
18. diet$ or nutrition$:ti,ab,kw (Word variations have been searched)
19. {and #17-#18}
20. (diet* or nutrition*) and (protein or fat or cholesterol or omega-3* or carbohydrates or glyc?emic index or fibre
or fiber or folate or folic acid):ti,ab,kw (Word variations have been searched)
21. (diet* or nutrition*) and (mediterranean or vegetarian or DASH or macrobiotic):ti,ab,kw (Word variations have
been searched)
22. (diet* or nutrition*) and (phosphorus or calcium or potassium or micronutrient* or vitamin*):ti,ab,kw (Word
variations have been searched)
23. (diet* or nutrition*) and (supplement* or amino acid* or keto acid*):ti,ab,kw (Word variations have been
searched)
24. (diet$ or nutrition*) and (advice* or education* or counselling):ti,ab,kw (Word variations have been searched)
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(Continued)
25. {or #1-#16, #19-#24}
26. MeSH descriptor: [Kidney Diseases] explode all trees
27. MeSH descriptor: [Renal Replacement Therapy] explode all trees
28. MeSH descriptor: [Renal Insufficiency] explode all trees
29. MeSH descriptor: [Renal Insufficiency, Chronic] explode all trees
30. dialysis:ti,ab,kw (Word variations have been searched)
31. hemodialysis or haemodialysis:ti,ab,kw (Word variations have been searched)
32. hemofiltration or haemofiltration:ti,ab,kw (Word variations have been searched)
33. hemodiafiltration or haemodiafiltration:ti,ab,kw (Word variations have been searched)
34. kidney disease* or renal disease* or kidney failure or renal failure:ti,ab,kw (Word variations have been searched)
35. ESRF or ESKF or ESRD or ESKD:ti,ab,kw (Word variations have been searched)
36. CKF or CKD or CRF or CRD:ti,ab,kw (Word variations have been searched)
37. CAPD or CCPD or APD:ti,ab,kw (Word variations have been searched)
38. predialysis or pre-dialysis:ti,ab,kw (Word variations have been searched)
39. MeSH descriptor: [Diabetic Nephropathies] this term only
40. diabetic kidney disease*:ti,ab,kw (Word variations have been searched)
41. diabetic nephropath*:ti,ab,kw (Word variations have been searched)
42. {or #26-#41}
43. {and #25, #42}
MEDLINE 1. Diet/
2. Diet Therapy/
3. Caloric Restriction/
4. Diabetic Diet/
5. Diet, Carbohydrate-Restricted/
6. Diet, Fat-Restricted/
7. Diet, Gluten-free/
8. Diet, Macrobiotic/
9. Diet, High-Fat/
10. Diet, Mediterranean/
11. Diet, Paleolithic/
12. Diet, Protein-Restricted/
13. Diet, Reducing/
14. Diet, Sodium-Restricted/
15. Diet, Vegetarian/
16. Diet, Atherogenic/
17. Diet Fads/
18. Diet, Cariogenic/
19. Diet, Western/
20. exp Dietary Carbohydrates/
21. Calcium, Dietary/
22. Potassium, Dietary/
23. exp Dietary Fats/
24. exp Dietary Fiber/
25. exp Dietary Proteins/
26. Dietary Supplements/
27. exp Micronutrients/
28. exp Nutritional Requirements/
29. Nutritional Status/
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(Continued)
30. Nutrition Therapy/
31. Energy Intake/
32. Fasting/
33. ketogenic diet/
34. Portion Size/ or Serving Size/
35. exp Keto Acids/
36. exp Amino Acids, Essential/
37. exp Amino Acids/
38. Folic Acid/
39. Patient Education as Topic/
40. (diet$ and (mediterranean or vegetarian or DASH)).tw.
41. (diet$ and (supplement$ or amino acid$ or amino acids or keto acid$)).tw.
42. ((diet$ or nutrition$) and (advice$ or education$ or counselling)).tw.
43. or/1-42
44. Kidney Diseases/
45. exp Renal Replacement Therapy/
46. Renal Insufficiency/
47. exp Renal Insufficiency, Chronic/
48. dialysis.tw.
49. (hemodialysis or haemodialysis).tw.
50. (hemofiltration or haemofiltration).tw.
51. (hemodiafiltration or haemodiafiltration).tw.
52. (kidney disease* or renal disease* or kidney failure or renal failure).tw.
53. (ESRF or ESKF or ESRD or ESKD).tw.
54. (CKF or CKD or CRF or CRD).tw.
55. (CAPD or CCPD or APD).tw.
56. (predialysis or pre-dialysis).tw.
57. or/44-56
58. Diabetic Nephropathies/
59. diabetic nephropath$.tw.
60. diabetic kidney$.tw.
61. or/58-60
62. Diabetes Mellitus/
63. exp diabetes mellitus, type 1/
64. exp diabetes mellitus, type 2/
65. or/62-64
66. proteinuria/ or albuminuria/
67. proteinuria$ or albuminuria$ or microalbuminuria$ or macroalbuminuria$).tw.
68. or/66-67
69. and/65,68
70. or/61,69
71. or/57,70
72. and/43,70
EMBASE 1. nutritional counseling/
2. nutrition education/
3. nutritional health/
4. nutritional assessment/
5. nutrition/
6. exp diet/
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(Continued)
7. exp diet therapy/
8. exp dietary intake/
9. exp diet restriction/
10. or/1-9
11. exp renal replacement therapy/
12. kidney disease/
13. chronic kidney disease/
14. kidney failure/
15. chronic kidney failure/
16. mild renal impairment/
17. stage 1 kidney disease/
18. moderate renal impairment/
19. severe renal impairment/
20. end stage renal disease/
21. renal replacement therapy-dependent renal disease/
22. kidney transplantation/
23. (hemodialysis or haemodialysis).tw.
24. (hemofiltration or haemofiltration).tw.
25. (hemodiafiltration or haemodiafiltration).tw.
26. dialysis.tw.
27. (CAPD or CCPD or APD).tw.
28. (kidney disease* or renal disease* or kidney failure or renal failure).tw
29. (CKF or CKD or CRF or CRD).tw.
30. (ESRF or ESKF or ESRD or ESKD).tw.
31. (predialysis or pre-dialysis).tw.
32. ((kidney or renal) adj (transplant* or graft* or allograft*)).tw
33. Diabetic Nephropathies/
34. diabetic nephropath$.tw.
35. diabetic kidney disease$.tw.
36. or/11-35
37. and/10,36
Appendix 2. Risk of bias assessment tool
Potential source of bias Assessment criteria
Random sequence generation
Selection bias (biased allocation to interventions) due to inade-
quate generation of a randomised sequence
Low risk of bias: Random number table; computer random num-
ber generator; coin tossing; shuffling cards or envelopes; throwing
dice; drawing of lots; minimization (minimization may be imple-
mented without a random element, and this is considered to be
equivalent to being random)
High risk of bias: Sequence generated by odd or even date of birth;
date (or day) of admission; sequence generated by hospital or
clinic record number; allocation by judgement of the clinician; by
preference of the participant; based on the results of a laboratory
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test or a series of tests; by availability of the intervention
Unclear: Insufficient information about the sequence generation
process to permit judgement
Allocation concealment
Selection bias (biased allocation to interventions) due to inade-
quate concealment of allocations prior to assignment
Low risk of bias: Randomisation method described that would not
allow investigator/participant to know or influence intervention
group before eligible participant entered in the study (e.g. central
allocation, including telephone, web-based, and pharmacy-con-
trolled, randomisation; sequentially numbered drug containers of
identical appearance; sequentially numbered, opaque, sealed en-
velopes)
High risk of bias:Using an open random allocation schedule (e.g. a
list of random numbers); assignment envelopes were used without
appropriate safeguards (e.g. if envelopes were unsealed or non-
opaque or not sequentially numbered); alternation or rotation;
date of birth; case record number; any other explicitly unconcealed
procedure
Unclear: Randomisation stated but no information on method
used is available
Blinding of participants and personnel
Performance bias due to knowledge of the allocated interventions
by participants and personnel during the study
Low risk of bias: No blinding or incomplete blinding, but the re-
view authors judge that the outcome is not likely to be influenced
by lack of blinding; blinding of participants and key study per-
sonnel ensured, and unlikely that the blinding could have been
broken
High risk of bias: No blinding or incomplete blinding, and the
outcome is likely to be influenced by lack of blinding; blinding
of key study participants and personnel attempted, but likely that
the blinding could have been broken, and the outcome is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Blinding of outcome assessment
Detection bias due to knowledge of the allocated interventions by
outcome assessors
Low risk of bias:Noblinding of outcome assessment, but the review
authors judge that the outcome measurement is not likely to be
influenced by lack of blinding; blinding of outcome assessment
ensured, and unlikely that the blinding could have been broken
High risk of bias: No blinding of outcome assessment, and the
outcome measurement is likely to be influenced by lack of blind-
ing; blinding of outcome assessment, but likely that the blinding
could have been broken, and the outcome measurement is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
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Incomplete outcome data
Attrition bias due to amount, nature or handling of incomplete
outcome data
Low risk of bias: No missing outcome data; reasons for missing
outcome data unlikely to be related to true outcome (for survival
data, censoring unlikely to be introducing bias); missing outcome
data balanced in numbers across intervention groups, with similar
reasons for missing data across groups; for dichotomous outcome
data, the proportion ofmissing outcomes comparedwith observed
event risk not enough to have a clinically relevant impact on the
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes not enough to have a clinically
relevant impact on observed effect size; missing data have been
imputed using appropriate methods
High risk of bias: Reason for missing outcome data likely to be
related to true outcome, with either imbalance in numbers or rea-
sons for missing data across intervention groups; for dichotomous
outcome data, the proportion ofmissing outcomes comparedwith
observed event risk enough to induce clinically relevant bias in
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes enough to induce clinically rel-
evant bias in observed effect size; ‘as-treated’ analysis done with
substantial departure of the intervention received from that as-
signed at randomisation; potentially inappropriate application of
simple imputation
Unclear: Insufficient information to permit judgement
Selective reporting
Reporting bias due to selective outcome reporting
Low risk of bias: The study protocol is available and all of the
study’s pre-specified (primary and secondary) outcomes that are of
interest in the review have been reported in the pre-specified way;
the study protocol is not available but it is clear that the published
reports include all expected outcomes, including those that were
pre-specified (convincing text of this nature may be uncommon)
High risk of bias: Not all of the study’s pre-specified primary out-
comes have been reported; one or more primary outcomes is re-
ported using measurements, analysis methods or subsets of the
data (e.g. subscales) that were not pre-specified; one or more re-
ported primary outcomes were not pre-specified (unless clear jus-
tification for their reporting is provided, such as an unexpected
adverse effect); one or more outcomes of interest in the review are
reported incompletely so that they cannot be entered in a meta-
analysis; the study report fails to include results for a key outcome
that would be expected to have been reported for such a study
Unclear: Insufficient information to permit judgement
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Other bias
Bias due to problems not covered elsewhere in the table
Low risk of bias: The study appears to be free of other sources of
bias.
High risk of bias: Had a potential source of bias related to the spe-
cific study design used; stopped early due to some data-dependent
process (including a formal-stopping rule); had extreme baseline
imbalance; has been claimed to have been fraudulent; had some
other problem
Unclear: Insufficient information to assess whether an important
risk of bias exists; insufficient rationale or evidence that an iden-
tified problem will introduce bias
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